Approval · Notice of Compliance 10802 · 2009
ADCIRCA: Notice of Compliance 10802
Issued November 25, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10802
- Date
- November 25, 2009
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
- Therapeutic class
- cGMP-specific phosphodiesterase type 5 inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADCIRCA | 02338327 | Cancelled Post Market |
Medicinal ingredients
- TADALAFIL 20 MG per TAB